Cargando…
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
OBJECTIVE: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices. METHODS: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data fr...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451044/ https://www.ncbi.nlm.nih.gov/pubmed/25911108 http://dx.doi.org/10.1212/WNL.0000000000001608 |